SCHEMBL8307935

SCHEMBL8307935

Cc1cc(C(O)CNC(C)COc2ccc(CC3SC(=O)NC3=O)cc2)cc(C)c1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.55
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
CISD1 Q9NZ45 1/20 0.51
FFAR1 O14842 8/20 0.47
PPARA Q07869 2/20 0.45
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8304952 0.85 PPARG (0.59) PPARGFFAR1PPARAMEN1CYP1A2
SCHEMBL8305245 0.84 PPARG (0.63) PPARGFFAR1CYP1A2CYP3A4CYP2C9
SCHEMBL8406934 0.84 PPARG (0.63) PPARGFFAR1CYP1A2CYP3A4CYP2C9
SCHEMBL8305247 0.84 PPARG (0.63) PPARGFFAR1CYP1A2CYP3A4CYP2C9
SCHEMBL8305440 0.84 PPARG (0.63) PPARGFFAR1CYP1A2CYP3A4CYP2C9
SCHEMBL8304617 0.82 PPARG (0.60) PPARGFFAR1PPARAMPC2CYP2C8
SCHEMBL8308137 0.80 PPARG (0.54) PPARGFFAR1PPARAMEN1ALDH1A1
SCHEMBL8974677 0.80 PPARG (0.57) PPARGFFAR1PPARAMEN1ALDH1A1
SCHEMBL8974649 0.79 FFAR1 (0.53) PPARGFFAR1PPARAMEN1ALDH1A1
SCHEMBL8974734 0.78 FFAR1 (0.56) PPARGFFAR1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0590793-B1 Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO CO (JP) 1999-10-13 EP disclosed
US-5436257-A Low toxicity SANKYO COMPANY, LIMITED (JP) 1995-07-25 US disclosed
EP-0590793-A1 Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses SANKYO COMPANY LIMITED (JP) 1994-04-06 EP disclosed